Skip to content

Search

Genocide in the Wildflower State Screening & Panel discussion

A powerful screening of truth telling that captures the stories of the Western Australia Stolen Generation.

Help shape the future of health & medical research in your community

Find out what our communities had to say about the draft Statement on Consumers and Community Involvement in Health and Medical Research.

New meningococcal strains bring increased risk in WA

A new study has confirmed the changing pattern of meningococcal disease in Western Australia.

2020 VTG Christmas Update

Coming up in 2021 Contact us We have a a study to suit every age range in 2021!  From babies at just six weeks for the FluBub Study, through to

Global consortium aims to protect babies from their first week of life

Babies are most vulnerable to life-threatening diseases in their first few weeks of life, yet current vaccines can’t be given until two months of age.

The Kids ‘Tall Poppies’ rise above the rest

Three The Kids researchers have been named amongst WA’s most outstanding young scientists for their efforts to ensure kids around the country have the chance to lead happy and healthy lives.

Whooping cough vaccine could be a new weapon in the fight against food allergies

Researchers from The Kids Research Institute Australia and Curtin University will use a $3.9 million grant from the National Health and Medical Research Council to investigate whether a type of whooping cough vaccine could provide bonus protection against food allergies and eczema.

New pneumococcal vaccine closes in on approval

Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.

Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024

In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.

Evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children

High nasopharyngeal pneumococcal carriage density is associated with severe pneumonia; however, little is known about factors that affect pneumococcal carriage density including pneumococcal vaccination. We describe pneumococcal density by clinical and demographic factors, and effect of 13-valent pneumococcal conjugate vaccine (PCV13) on density in Papua New Guinea (PNG), Lao People’s Democratic Republic (Lao PDR) and Mongolia, 3–6 years following national PCV13 introduction.